Adjuvant efficacy of mOMV against avian influenza virus infection in mice = 인플루엔자 바이러스 감염을 예방하는 mOMV의 백신 아쥬번트 효능

Cited 1 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorB J Lee-
dc.contributor.authorSang Ho Lee-
dc.contributor.authorM S Song-
dc.contributor.authorP N Q Pascua-
dc.contributor.authorH I Kwon-
dc.contributor.authorS J Park-
dc.contributor.authorE H Kim-
dc.contributor.authorA Decano-
dc.contributor.authorS M Kim-
dc.contributor.authorG J Lim-
dc.contributor.authorDoo Jin Kim-
dc.contributor.authorKyu Tae Chang-
dc.contributor.authorSang-Hyun Kim-
dc.contributor.authorY K Choi-
dc.date.accessioned2017-04-19T09:44:07Z-
dc.date.available2017-04-19T09:44:07Z-
dc.date.issued2013-
dc.identifier.issn1225-8873-
dc.identifier.uri10.1007/s12275-013-3411-3ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/11567-
dc.description.abstractHighly pathogenic avian influenza H5N1 viruses are found chiefly in birds and have caused severe disease and death in infected humans. Development of influenza vaccines capable of inducing heterosubtypic immunity against a broad range of influenza viruses is the best option for the preparedness, since vaccination remains the principal method in controlling influenza viral infections. Here, a mOMV-adjuvanted recombinant H5N2 (rH5N2) whole virus antigen vaccine with A/Environment/Korea/W149/06(H5N1)-derived H5 HA and A/Chicken/Korea/ma116/04(H9N2)-derived N2 NA in the backbone of A/Puerto Rico/8/34(H1N1) was prepared and generated by reverse genetics. Groups of mice were vaccinated by a prime-boost regime with the rH5N2 vaccine (1.75 μg of HA with/without 10 μg mOMV or aluminum hydroxide adjuvant for comparison). At two weeks post-immunizations, vaccinated mice were challenged with lethal doses of 103.5 EID50/ml of H5N1 or H9N2 avian influenza viruses, and were monitored for 15 days. Both mOMV- and alum-adjuvant vaccine groups had high survival rates after H5N1 infection and low levels of body weight changes compared to control groups. Interestingly, the mOMV-adjuvanted group induced better cross-reactive antibody responses serologically and promoted cross-protectivity against H5N1 and H9N2 virus challenges. Our results suggest that mOMV could be used as a vaccine adjuvant in the development of effective vaccines used to control influenza A virus transmission.-
dc.publisherMicrobiological Society Korea-
dc.titleAdjuvant efficacy of mOMV against avian influenza virus infection in mice = 인플루엔자 바이러스 감염을 예방하는 mOMV의 백신 아쥬번트 효능-
dc.title.alternativeAdjuvant efficacy of mOMV against avian influenza virus infection in mice-
dc.typeArticle-
dc.citation.titleJournal of Microbiology-
dc.citation.number5-
dc.citation.endPage688-
dc.citation.startPage682-
dc.citation.volume51-
dc.contributor.affiliatedAuthorSang Ho Lee-
dc.contributor.affiliatedAuthorDoo Jin Kim-
dc.contributor.affiliatedAuthorKyu Tae Chang-
dc.contributor.affiliatedAuthorSang-Hyun Kim-
dc.contributor.alternativeName이병재-
dc.contributor.alternativeName이상호-
dc.contributor.alternativeName송민석-
dc.contributor.alternativeNamePascua-
dc.contributor.alternativeName권혁일-
dc.contributor.alternativeName박수진-
dc.contributor.alternativeName김은하-
dc.contributor.alternativeNameDecano-
dc.contributor.alternativeName김세미-
dc.contributor.alternativeName임교진-
dc.contributor.alternativeName김두진-
dc.contributor.alternativeName장규태-
dc.contributor.alternativeName김상현-
dc.contributor.alternativeName최영기-
dc.identifier.bibliographicCitationJournal of Microbiology, vol. 51, no. 5, pp. 682-688-
dc.identifier.doi10.1007/s12275-013-3411-3-
dc.subject.keywordavian influenza A virus-
dc.subject.keywordH5N2 vaccine-
dc.subject.keywordmOMV adjuvant-
dc.subject.localavian influenza A virus-
dc.subject.localH5N2 vaccine-
dc.subject.localmOMV adjuvant-
dc.description.journalClassY-
Appears in Collections:
Division of Research on National Challenges > Infectious Disease Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.